Metabolic peptides are at the forefront of modern research into weight management, insulin sensitivity, and energy metabolism. Tirzepatide is being studied for its potential role in metabolic regulation and related pathways.
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity (Mounjaro/Zepbound). Clinical trials showed weight reductions up to 22%, representing a new class of metabolic therapy.
Also Known As
Mounjaro, Zepbound, LY3298176
What is Tirzepatide?
Tirzepatide is classified under the Metabolic category of peptides. A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity (Mounjaro/Zepbound). Clinical trials showed weight reductions up to 22%, representing a new class of metabolic therapy.
Mechanism of Action: A dual GIP/GLP-1 receptor agonist that activates both incretin pathways simultaneously. The GIP receptor activation provides additional metabolic benefits beyond GLP-1 alone, including enhanced insulin sensitivity and potentially greater effects on fat metabolism.
Metabolic Research & Applications
Primary Research Areas: Type 2 diabetes, obesity, metabolic syndrome, cardiovascular outcomes, NASH.
Key Research Findings: The SURMOUNT-1 trial showed unprecedented weight loss of up to 22.5% at the highest dose. SURPASS trials demonstrated superior HbA1c reduction compared to semaglutide. The dual agonist approach represents a paradigm shift in metabolic therapy.
Safety Profile & Considerations
Similar GI side effects to GLP-1 agonists. Carries same thyroid C-cell tumor warning as GLP-1 RAs. Hypoglycemia risk when combined with insulin or sulfonylureas.
Related Research Topics
Understanding Tirzepatide requires familiarity with these related concepts in metabolic research. Each topic represents a broader field that intersects with current peptide research.
References & Further Reading
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
Stay Updated on Peptide Research
Get the latest science-backed articles on peptides delivered to your inbox.